After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: …

Though it has struggled to live up to early commercial expectations, Amgen’s cholesterol treatment Repatha has largely had the best of its rival in the …